Responses
Clinical/translational cancer immunotherapy
Original research
Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy
Compose a Response to This Article
Other responses
No responses have been published for this article.
